General Information |
| Clinical trials phase |
Phase 1 |
| Start date (estimated) |
2023-05-01 |
| Clinical feature |
| Label |
head and neck cancer |
| Link |
http://purl.obolibrary.org/obo/DOID_11934 |
| Description |
An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx. |
|
Administrative Information |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-jRCTa030220741 |
| Other study identifiers |
| Name |
jRCTa030220741 |
| Description |
Japan Registry of Clinical Trials (jRCT) |
|
| Source weblink |
https://jrct.niph.go.jp/en-latest-detail/jRCTa030220741 |
| Public contact |
| Email |
byoin-kshien@chiba-u.jp |
| Public email |
byoin-kshien@chiba-u.jp |
| First name |
Shigemasa |
| Last name |
Mori |
| Phone |
+81-43-222-7171 |
| City |
Chiba |
| Country |
|
|
| Sponsors |
Tomohisa Iinuma
|
Cells |
| Which differentiated cell type is used |
| Label |
natural killer cell |
| Link |
http://purl.obolibrary.org/obo/CL_0000623 |
| Description |
A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells. |
|
Recruitment |
| Recruitment Status |
Unknown Status |
| Comment recruitment status |
Pending |
| Estimated number of participants |
6 |
